News

Welcome to the CLINUVEL News page. Discover the latest in clinical, corporate, and regulatory updates.

CLINUVEL completes pre-clinical study of SCENESSE® as combination therapy

2016 Announcements

02.08.2016

Appendix 4C – Q4 FY16

2016 Announcements

28.07.2016

FDA accepts SCENESSE® clinical data package for NDA submission

2016 Announcements

17.07.2016

FDA awards SCENESSE® Fast Track designation for treatment of EPP

2016 Announcements

05.07.2016

CLINUVEL’s SCENESSE® launched in Europe

2016 Announcements

20.06.2016

CLINUVEL added to Nasdaq International Designation

2016 Announcements

31.05.2016

SCENESSE® treatment in Europe

2016 Announcements

17.05.2016

Appendix 4C – Q3 FY16

2016 Announcements

29.04.2016

Form 604

2016 Announcements

11.04.2016

CLINUVEL Newsletter – April 2016

2016 Announcements

04.04.2016

NICE Highly Specialised Technology workshop reviews SCENESSE®

2016 Announcements

23.03.2016

s.708A Notice

2016 Announcements

18.03.2016

Appendix 3B

2016 Announcements

18.03.2016

.

Go To Top